Exploring the Potential of Immunotherapy in Small Bowel Adenocarcinoma
DOI:
https://doi.org/10.58445/rars.1175Keywords:
Immunotherapy, Small Bowel Adenocarcinoma, CancerAbstract
Cancer is characterized by the uncontrolled growth and spread of abnormal cells in the body and remains a formidable challenge in modern medicine. The immune system consists of innate and adaptive components that play the role of the body's defense line against any abnormal cells, including cancerous ones. However, cancer cells can evade the immune system through various mechanisms, posing a significant obstacle to effective treatment. Small Bowel Adenocarcinoma (SBA), a rare malignancy of the gastrointestinal tract, presents unique challenges due to limited treatment options and relatively poor outcomes. Recent advances in immunotherapy offer promising avenues for addressing these challenges. Immunotherapy harnesses the body's immune system to recognize and target cancer cells specifically, offering a potentially transformative approach to SBA treatment. In this review, we will discuss small-bowel adenocarcinoma with the therapy of immune checkpoint inhibitors (ICIs) and recognize the ongoing clinical trials in immunotherapy to expand its potential as a wide approach by exploring its effectiveness.
References
Christodoulidis, G., Kouliou, M. N., & Koumarelas, K. E. (2024). Immune signature of small bowel adenocarcinoma and the role of tumor microenvironment. World Journal of Gastroenterology, 30(8), 794–798. https://doi.org/10.3748/wjg.v30.i8.794
Gelsomino, F., Balsano, R., Stefania De Lorenzo, & Garajová, I. (2022). Small Bowel Adenocarcinoma: From Molecular Insights to Clinical Management. Current Oncology (Toronto), 29(2), 1223–1236. https://doi.org/10.3390/curroncol29020104
Goodman, M. T., Matsuno, R. K., & Shvetsov, Y. B. (2013). Racial and Ethnic Variation in the Incidence of Small-Bowel Cancer Subtypes in the United States, 1995–2008. Diseases of the Colon & Rectum, 56(4), 441–448. https://doi.org/10.1097/dcr.0b013e31826b9d0a
Khan, S., Khan, S. A., Luo, X., Fattah, F. J., Saltarski, J., Gloria-McCutchen, Y., Lu, R., Xie, Y., Li, Q., Wakeland, E., & Gerber, D. E. (2019). Immune dysregulation in cancer patients developing immune-related adverse events. British Journal of Cancer, 120(1), 63–68. https://doi.org/10.1038/s41416-018-0155-1
Khosla, D., Dey, T., Madan, R., Gupta, R., Goyal, S., Kumar, N., & Kapoor, R. (2022). Small bowel adenocarcinoma: An overview. World Journal of Gastrointestinal Oncology, 14(2), 413–422. https://doi.org/10.4251/wjgo.v14.i2.413
Kunz, P. L. (n.d.). Small Intestine Adenocarcinoma. Yale Medicine. https://www.yalemedicine.org/conditions/small-intestine-adenocarcinoma
Ocasio Quinones, G. A., Khan Suheb, M. Z., & Woolf, A. (2024). Small Bowel Cancer. PubMed; StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK560725/#:~:text=Despite%20the%20wide%20spectrum%20of
Phillips, C. (2023, February 23). Is Immunotherapy the Only Treatment Some People Need? - NCI. Www.cancer.gov. https://www.cancer.gov/news-events/cancer-currents-blog/2023/neoadjuvant-immunotherapy-only-treatment
Small Bowel Cancer - Types of Treatment. (2012, June 25). Cancer.net. https://www.cancer.net/cancer-types/small-bowel-cancer/types-treatment
Tim de Back, Nijskens, I., Pascale Schafrat, Chalabi, M., Geert Kazemier, Vermeulen, L., & Sommeijer, D. W. (2023). Evaluation of Systemic Treatments of Small Intestinal Adenocarcinomas. JAMA Network Open, 6(2), e230631–e230631. https://doi.org/10.1001/jamanetworkopen.2023.0631
Vitiello, F., Stefano Cereda, Foti, S., Liscia, N., Mazza, E., Ronzoni, M., & Stefano Cascinu. (2023). Immunotherapy in small bowel adenocarcinoma: a potential role? Immunological Medicine, 47(1), 1–5. https://doi.org/10.1080/25785826.2023.2220938
Downloads
Posted
Categories
License
Copyright (c) 2024 Alvina Wong, Ashley Pearson
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.